YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI,Jan. 21,2025--YolTech Therapeutics,a clinical-stage gene editing company dedicated to delivering lifelong cures,announced the initiation of a clinical trial for YOLT-204,an investigational th